



## Survey report MQ 2015-4 U3 Drugs of abuse

### Amphetamine

	Target value	Participant	Conform	Conform%
Roche Cobas	Negativ	6	6	100
Triage 8	Negativ	9	9	100
Syva Rapid Test	Negativ	3	3	100
Intex	Negativ	5	5	100
Syntron Quik	Negativ	1	1	100
Triage TOX	Negativ	11	11	100
Other quantitativ	Negativ	12	12	100
Other Rapid tests	Negativ	48	48	100
<b>TOTAL</b>		<b>95</b>	<b>95</b>	<b>100</b>

### Methamphetamine

	Target value	Participant	Conform	Conform%
Intex	Negativ	2	2	100
Syva Rapid Test	Negativ	2	2	100
Triage TOX	Negativ	11	11	100
Other Rapid tests	Negativ	21	21	100
<b>TOTAL</b>		<b>36</b>	<b>36</b>	<b>100</b>

### Ecstasy pos/neg

	Target value	Participant	Conform	Conform%
Other Rapid tests	Negative	<b>11</b>	<b>11</b>	<b>100</b>

### Barbiturate

	Target value	Participant	Conform	Conform%
Cobas	Negativ	6	6	100
Triage 8	Negativ	9	9	100
Intex	Negativ	1	1	100
Triage TOX	Negativ	11	11	100
Other quantitativ	Negativ	8	8	100
Other Rapid tests	Negativ	23	23	100
<b>TOTAL</b>		<b>58</b>	<b>58</b>	<b>100</b>

**Benzodiazepine***1000 µg Nordazepam*

	Target value	Participant	Conform	Conform%
Cobas	Positive	7	7	100
Triage 8	Positive	9	9	100
Intex	Positive	11	11	100
Syntron Quik	Positive	1	1	100
Triage TOX	Positive	11	11	100
Other quantitativ	Positive	14	14	100
Other Rapid tests	Positive	57	56	98
<b>TOTAL</b>		<b>110</b>	<b>109</b>	<b>99</b>

**Cannabinoide***125 µg 11-Nor-Δ9-THC-Carbonsäure, 125 µg Δ9-THC*

	Target value	Participant	Conform	Conform%
Cobas	Positive	8	8	100
Triage 8	Positive	9	9	100
Syva Rapid Test	Positive	6	6	100
Intex	Positive	12	11	92
Syntron Quik	Positive	1	1	100
Triage TOX	Positive	11	11	100
Other quantitativ	Positive	15	14	93
Other Rapid tests	Positive	62	57	92
<b>TOTAL</b>		<b>124</b>	<b>117</b>	<b>94</b>

**Cocain**

	Target value	Participant	Conform	Conform%
Cobas	Negative	7	7	100
Triage 8	Negative	9	9	100
Syva Rapid Test	Negative	5	5	100
Intex	Negative	10	10	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	11	11	100
Other quantitativ	Negative	15	15	100
Other Rapid tests	Negative	61	61	100
<b>TOTAL</b>		<b>119</b>	<b>119</b>	<b>100</b>

**LSD**

	Target value	Participant	Conform	Conform%
Cobas	Negative	1	1	100

**Methadon**

	Target value	Participant	Conform	Conform%
Cobas	Negative	7	7	100
Triage 8	Negative	9	9	100
Intex	Negative	11	11	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	11	11	100
Other quantitativ	Negative	14	14	100
Other Rapid tests	Negative	47	47	100
<b>TOTAL</b>		<b>100</b>	<b>100</b>	<b>100</b>

**Methaqualon**

	Target value	Participant	Conform	Conform%
All	Negative	1	1	100

**Opiate**

	Target value	Participant	Conform	Conform%
Cobas	Negative	7	7	100
Triage 8	Negative	9	9	100
Syva Rapid Test	Negative	5	5	100
Intex	Negative	12	12	100
Syntron Quik	Negative	1	1	100
Triage TOX	Negative	11	11	100
Other quantitativ	Negative	16	16	100
Other Rapid tests	Negative	58	58	100
<b>TOTAL</b>		<b>119</b>	<b>119</b>	<b>100</b>

**Paracetamol**

	Target value	Participant	Conform	Conform%
Triage TOX	Negative	11	10	91

**Phencyclidin**

	Target value	Participant	Conform	Conform%
Triage TOX	Negative	11	11	100
Other Rapid tests	Negative	9	9	100
<b>TOTAL</b>		<b>20</b>	<b>20</b>	<b>100</b>

**Tricyclic Antidepressiva**

	Target value	Participant	Conform	Conform%
Triage 8	Negative	8	8	100
Triage TOX	Negative	11	11	100
All methods	Negative	14	12	86
<b>TOTAL</b>		<b>33</b>	<b>31</b>	<b>91</b>

Zürich, 1.12.2015  
Dr. R. Fried